Zevra Therapeutics (ZVRA) Interest Expenses (2014 - 2026)

Zevra Therapeutics has reported Interest Expenses for 13 years, with the latest figure at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 13.1% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $7.7 million (down 10.09% YoY), and the FY2025 full-year result was $8.0 million, up 8.52% from the prior year.
• Interest Expenses for Q1 2026 stood at $1.7 million, down from $1.9 million in the prior quarter.
• The five-year high for Interest Expenses was $2.3 million in Q3 2024, with the low at $182000.0 in Q1 2023.
• Historically, Interest Expenses has averaged $1.3 million across 5 years, with a median of $1.8 million in 2025.
• Annual changes were most pronounced in 2022 — Interest Expenses jumped 6600.0% — and 2026, when it retreated 13.1%.
• Zevra Therapeutics' Interest Expenses stood at $335000.0 in 2022, then surged by 125.67% to $756000.0 in 2023, then soared by 190.21% to $2.2 million in 2024, then slipped by 11.21% to $1.9 million in 2025, then declined by 12.17% to $1.7 million in 2026.
• The last three Interest Expenses figures came in at $1.7 million (Q1 2026), $1.9 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.